Alnylam Pharmaceuticals, Inc. (ALNY)

Quick facts

Marketed products

• Amvuttra · Neuroscience · revenue 1100
  Amvuttra works by silencing the production of abnormal TTR protein through RNA interference.
• Onpattro · Neuroscience · revenue 700
  Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA.
• Onpattro · Neuroscience · revenue 700
  Onpattro works by silencing the production of abnormal TTR protein through RNA interference.
• Givlaari · Neuroscience · revenue 400
  Givlaari works by binding to and silencing the messenger RNA (mRNA) that produces the enzyme aminolevulinate synthase 1 (ALAS1), which is overproduced in patients with hepatic porphyria.
• Oxlumo · Metabolic · revenue 200
  Oxlumo works by binding to and silencing the mRNA that produces the enzyme Hydroxyacid oxidase 1, which is overactive in patients with Primary hyperoxaluria, type I.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Alnylam Pharmaceuticals, Inc. portfolio CI brief
• Alnylam Pharmaceuticals, Inc. pipeline updates RSS